MedPath

Epidermal Nerve Fibre Density Reduction as a Function of Application Time of topical high-dose and low-dose Capsaici

Phase 4
Conditions
Healthy volunteers
Registration Number
DRKS00004587
Lead Sponsor
niversitätsklinik Wien
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
12
Inclusion Criteria

healthy male and female volunteers 18 > age < 80
informed consent
dermal and neurological integrity of the foresides of the thighs
female volunteers - not pregnant or breast feeding

Exclusion Criteria

anamnestic injury or surgery of the thighs
Nerved damage (Nervus femoralis or lumbal nerval roots 2-4)

lack or different information by testing of sensitivity disturbance, impaired experience of pain and temperature in the area of the fore of the thighs

prior use of Qutenza or other topical capsaicin preparations in the area of the firesides of the thighs in between 3 months prior to the start of the investigation

known hypersensitivity to capsaicin

known hypersensitivity to local anesthetic ointment Emla- Creme® (Lidocaine, Prilocaine, Macrogolglycerolhydroxystearat, Carbomer)
known hypersensitivity to Ultrasicc® (Petrolatum, Cera Microcristallina, Stearylalkohol, Macrogolstearat 2000, Polyacrylacid, Natriumedetat, Propyl-4-hydroxybenzoat) as carrier substance of the Capsaicin 0,05% Creme
known hypersensitivity to Qutenza® (Capsaicin, silicone-adhesives, Diethylenglycolmonoethylether, Dimeticone, Ethylcellulose) cleansing gel (Macrogol 300, Carbomer 1382, Natriumedetat, Butylhydroxyanisol)

known hypersensitivity to paracetamol

unstable hypertension, current cardiovascular event, methaemoglobinaemia, G6PDH-Insufficiency, hepatic insufficiency, use of antiarrhythmics, known alcohol or drug abuse

participation in another trial
Pregnancy or breast feeding

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of ENF density (determined with histological evaluation of skin biopsies) of skin areas treated with low-dose capsaicin and skin areas treated with high-dose capsaicin in skin biopsies taken one week and five weeks after the exposure, as a function of application time respectively.
Secondary Outcome Measures
NameTimeMethod
investiagtion of the mentioned results for male and female volunteers (gender aspect)<br>expectation: no gender specific disparity<br><br>investiagtion of the maximum systolic and diastolic blood pressure during capsaicin exposure and comparison to values before starting of the investigation<br><br>expectation: no significant increase in blood pressure during the capsaicin treatment
© Copyright 2025. All Rights Reserved by MedPath